CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

This Phase 3 study tests the long-term safety of itepekimab, an injected drug, in 380 adults with chronic sinusitis and nasal polyps that are hard to control. Participants previously completed a one-year study on itepekimab. The trial lasts up to 72 weeks and also checks if the d…

This Phase 3 trial tests itepekimab, an injectable drug, in 216 adults with chronic sinusitis and nasal polyps that are not well-controlled by standard nasal sprays. Participants receive itepekimab or a placebo for 52 weeks, plus a nasal spray. The study measures changes in polyp…

This study looks at the long-term safety and effectiveness of lunsekimig, an injectable drug, in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants have already completed a previous lunsekimig study and will continue treatment for up to 52 w…

This Phase 3 trial tests an experimental drug called GR1802 for adults with severe chronic rhinosinusitis with nasal polyps. The goal is to see if the drug can shrink polyps, ease congestion, and reduce the need for surgery or steroids. 228 participants will receive either GR1802…

This study tests a biologic drug called tezepelumab (Tezspire) in 181 adults with chronic sinusitis and nasal polyps who are eligible for surgery. Participants receive injections every 4 weeks for 24 weeks. The goal is to see if the drug reduces nasal congestion and other sinus s…

This study tests a drug called itepekimab in adults with chronic sinusitis and nasal polyps that are not well controlled by standard treatments. About 231 participants will receive either itepekimab or a placebo as an add-on to their usual nasal spray. The goal is to see if the d…

This study follows 100 adults with severe chronic sinusitis and nasal polyps who are starting biologic treatments. Researchers want to see how these drugs improve quality of life, smell, and breathing over 6 months, and track any side effects. The goal is to learn which patients …

This study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…